Auxilium’s Peyronie’s Strategy: Start With Few Urologists, Broad Patient Population

This article was originally published in The Pink Sheet Daily

06 Dec 2013
News

Sarah Karlin pinkeditor@informa.com

Executive Summary

Xiaflex is first drug approved for Peyronie’s disease; initial marketing will focus on physicians that already provide invasive treatment.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical North America United States

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS075228

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS075228

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Auxilium’s Peyronie’s Strategy: Start With Few Urologists, Broad Patient Population

News

Executive Summary

Related Content

Endo Makes A Play For Auxilium, But QLT Deal Gets In The Way

Xiaflex Sales Still Slow, But Other Indications In The Works

Auxilium's Xiaflex Clears FDA With REMS To Educate Doctors On Safe Injection Techniques

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert